Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAetna Oxaliplatin Coverage & Prior Auth | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0683

    Oxaliplatin (Eloxatin)

    Customize your policy alerts

    Sign up for Aetna Policy 0683 alerts

    Get alerted when Policy 0683 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity criteria, continuation rules, coding, FDA-approved indications, compendial uses, dosing guidance, and investigational exclusions for oxaliplatin (Eloxatin). Applies to Aetna members and providers submitting requests for coverage of oxaliplatin.

    Policy Summary
    PayerAetna
    PolicyOxaliplatin (Eloxatin)
    Policy CodePolicy 0683
    Change TypeNo material changes
    Effective DateMar 30, 2004
    Last ReviewNov 21, 2023
    Next Review DateSep 26, 2024
    Key ActionObtain prior authorization for J9263 and document indication, planned regimen and dose consistent with labeling (e.g., oxaliplatin 85 mg/m2 q2 weeks with 5-FU/LV).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Indications listed as medically necessary
    J9263HCPCS code for oxaliplatin (per 0.5 mg)
    85 mg/m2Common dose (Day 1)
    Up to 12 cyclesAdjuvant duration
    ~11 typesExperimental indications
    09/26/2024Next review

    Coverage Criteria for Oxaliplatin (Eloxatin)

    Initial Approval - Listed Indications

    Aetna considers oxaliplatin (Eloxatin) medically necessary for the following indications:

    Listed indications: Member has one of the specifically listed tumor types: ampullary adenocarcinoma; metastatic anal carcinoma; B-cell lymphomas (including follicular lymphoma grade 1-2, histologic transformation to diffuse large B-cell lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, high-grade B-cell lymphomas, HIV-related B-cell lymphomas, and post-transplant lymphoproliferative disorders); bladder cancer (urothelial and non-urothelial, including variant histology); chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); classic Hodgkin lymphoma; colorectal cancer (including anal adenocarcinoma, appendiceal adenocarcinoma, colon and rectal cancers); esophageal and esophagogastric junction cancers; gastric cancer; biliary tract cancers (intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer); neuroendocrine and adrenal tumors (including GI, lung, thymus NETs; pancreatic NETs; well differentiated grade 3 NETs; poorly differentiated/large or small cell carcinoma/mixed neuroendocrine–non-neuroendocrine neoplasms); occult primary tumors (cancer of unknown primary); epithelial ovarian, fallopian tube, and primary peritoneal cancers (including carcinosarcoma, clear cell, mucinous, grade 1 endometrioid, low‑grade serous/borderline epithelial tumors, and malignant germ cell tumor residual disease); pancreatic adenocarcinoma; primary cutaneous lymphomas (including mycosis fungoides/Sezary syndrome and primary cutaneous CD30+ disorders); small bowel adenocarcinoma; T-cell lymphomas (including peripheral T‑cell lymphomas, adult T‑cell leukemia/lymphoma, hepatosplenic T‑cell lymphoma, extranodal NK/T‑cell lymphoma, and breast implant–associated ALCL); and testicular cancer.
    Policy Summary
    PayerAetna
    PolicyOxaliplatin (Eloxatin)
    Policy CodePolicy 0683
    Change TypeNo material changes
    Effective DateMar 30, 2004
    Last ReviewNov 21, 2023
    Next Review DateSep 26, 2024
    Key ActionObtain prior authorization for J9263 and document indication, planned regimen and dose consistent with labeling (e.g., oxaliplatin 85 mg/m2 q2 weeks with 5-FU/LV).
    SourceLink
    On This Page
    Coverage Criteria for Oxaliplatin (Eloxatin)Covered Regimens and DosingCoding and AdministrationProvider Actions and Authorization RequirementsLine of Therapy GuidanceBiomarker and Test RequirementsDefinitions and Drug InformationBackground and Evidence SummaryRevision History & Policy Dates

    Continuation of Therapy

    Continuation of therapy

    Continuation criteria: Continuation of oxaliplatin therapy is medically necessary for an indication listed in Section I when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

    Medically Necessary Indications and Dosing

    Covered when ALL of the following are met

    Adjuvant colon cancer (stage III): Patient has stage III colon cancer following complete surgical resection and oxaliplatin is planned as adjuvant therapy in combination with infusional 5‑fluorouracil and leucovorin (per FDA‑approved indication).
    Advanced/metastatic colorectal cancer (first‑line): Oxaliplatin is planned in combination with infusional 5‑fluorouracil/leucovorin or capecitabine for first‑line treatment of unresectable, advanced, or metastatic colon or rectal carcinoma (FDA and USP‑supported first‑line indication).
    Dosing consistency with labeling: Planned regimen and dosing are consistent with product labeling (eg, oxaliplatin 85 mg/m2 IV on Day 1 every 14 days given with leucovorin and 5‑FU per the Eloxatin prescribing information) or documented reduced doses per toxicity guidance (eg, reduce to 75 mg/m2 in adjuvant setting or 65 mg/m2 in advanced disease for specified toxicities).

    Includes dose‑reduction and discontinuation guidance for neurosensory and hematologic toxicities; never dilute final preparation with sodium chloride or other chloride‑containing solutions.

    Off-label or specialty-supported indications

    Covered (often off‑label) when supported by clinical evidence or specialty standards and appropriate documentation

    Esophageal cancer: Oxaliplatin may be used in multimodality regimens for primary, recurrent, or metastatic esophageal carcinoma in patients with adequate performance status (eg, ECOG ≤2) as supported by phase II studies and guideline mentions.
    Gastric cancer: Oxaliplatin‑containing regimens are accepted off‑label for advanced gastric cancer with trial response rates reported in the 40–60% range and may be used when clinically appropriate.
    Hepatobiliary cancers (biliary tract): FOLFOX is an accepted second‑line regimen after gemcitabine+cisplatin for advanced biliary tract cancers based on phase‑III validation and may be considered off‑label where indicated.
    Non‑Hodgkin's lymphoma (relapsed/refractory B‑cell): Oxaliplatin used alone or in combination (eg, R‑GemOx, R‑ADOx, R‑GIFOX) may be used for relapsed/refractory B‑cell lymphomas in patients not eligible for high‑dose therapy or transplantation based on phase II data showing activity.

    Supported systemic indications

    Coverage‑aligned clinical contexts and evidence summaries (documented trial/guideline support):

    Relapsed/refractory B‑cell lymphoma: Oxaliplatin in combination regimens (eg, R‑GemOx, R‑GIFOX) is supported by phase II trials reporting high overall response rates and acceptable tolerability in patients not suitable for high‑dose therapy or ASCT consolidation.
    Pancreatic adenocarcinoma: Oxaliplatin in combination (eg, GEMOX or with 5‑FU) is supported by randomized and phase II data and by NCCN guidance for use in locally advanced/metastatic disease in patients with good performance status and as subsequent therapy in selected patients.
    Recurrent epithelial ovarian cancer: NCCN guidelines list oxaliplatin as an acceptable alternative regimen for recurrent epithelial ovarian cancer in patients with prior partial responses to platinum/taxane therapy.
    Neuroendocrine tumors: GEMOX or capecitabine+oxaliplatin has evidence of activity and is listed as NCCN category 2A for pancreatic NETs (category 3 for carcinoid tumors) when systemic cytotoxic therapy is indicated.
    Triple‑negative metastatic breast cancer: Platinum‑containing regimens may provide small survival/PFS benefit in selected mTNBC subgroups but are associated with increased toxicity; use requires careful consideration of benefit/risk and supporting documentation.

    Loco-regional (HIPEC/PIPAC) applications — investigational

    Investigational or emerging loco‑regional applications:

    PIPAC/HIPEC oxaliplatin use (investigational): Use of oxaliplatin administered via HIPEC or PIPAC for peritoneal metastasis is investigational; available evidence consists of phase I/II studies and systematic reviews with heterogeneous, non‑randomized data and dose‑escalation trials (PIPAC starting ~45–92 mg/m2 with escalation reported up to 300 mg/m2).

    Recommend use only in clinical trials or documented investigational programs with informed consent and safety monitoring.

    Evidence-supported contexts

    Evidence‑supported uses and contexts summarized in this document section

    Peritoneal metastasis / PIPAC‑OX: PIPAC with oxaliplatin is being studied for peritoneal metastasis; current evidence may inform future randomized trials but the precise therapeutic role is undetermined.
    Small bowel adenocarcinoma: 5‑FU plus platinum compounds (including limited oxaliplatin cases) showed an ORR ~21% with median PFS/OS of approximately 8 and 14 months in small retrospective series; evidence is limited.
    NSCLC: Phase II trials of oxaliplatin‑based doublets (eg, oxaliplatin+gemcitabine) demonstrated activity comparable to carboplatin regimens with potentially milder hematologic toxicity; phase III confirmation is needed.
    Cancer of unknown primary (CUP): Oxaliplatin plus capecitabine showed activity as salvage therapy in CUP (ORR ~19%, median PFS 3.7 months, OS 9.7 months) and may be considered when a GI primary is suspected.
    SCCHN and melanoma: Small phase II studies report modest activity for oxaliplatin‑containing regimens in refractory SCCHN and limited activity in previously treated melanoma.
    Neuroendocrine tumors: GEMOX demonstrated partial responses in NETs with noted neurotoxicity; MGMT methylation status may influence selection between ALKY agents and GEMOX per analyses.
    Urothelial/bladder and cervical cancer: Available reviews and series do not support oxaliplatin as standard for many urothelial contexts; paclitaxel+oxaliplatin showed activity in recurrent/metastatic cervical cancer (ORR ~22%) but with substantial neuropathy—use guided by specialist judgement.
    Hepatocellular carcinoma (HCC): Systematic review/meta‑analysis reported pooled response rate ~16.8% for oxaliplatin‑based regimens in advanced HCC with median PFS ~4.2 months and OS ~9.3 months, supporting consideration in selected patients.
    AML (relapsed/refractory): Phase I studies of oxaliplatin combined with cytarabine and fludarabine showed anti‑leukemic activity but notable toxicity; schedule/dose optimization is required before routine use.
    Testicular germ cell tumors (relapsed/cisplatin‑refractory): GEMOX and gemcitabine+oxaliplatin regimens produced response rates (eg, 46% in one series) and some durable remissions, and may be considered as salvage options after cisplatin failure.
    Advanced gastric cancer — PD‑1 inhibitor combinations: Network meta‑analysis data indicate PD‑1 inhibitors plus oxaliplatin‑based chemotherapy provide similar or improved outcomes versus PD‑1 plus cisplatin‑based chemotherapy; in patients with PD‑L1 CPS ≥1, OS was significantly prolonged (HR 0.75) and PFS favored oxaliplatin combinations (HR 0.72).

    Aetna considers oxaliplatin (Eloxatin) experimental and investigational for a set of tumor types where effectiveness has not been established. These include: acute myeloid leukemia; breast cancer; cervical cancer; endometrial cancer; head and neck cancer; hepatocellular cancer; melanoma; mesothelioma; neuroendocrine tumors of the GI tract (except pancreas and poorly differentiated NEC), lung, and thymus; non-small cell lung cancer; prostate cancer; and urethral cancer. Use for these indications may be denied because evidence of benefit is lacking.

    Pressurized intra-peritoneal aerosol chemotherapy (PIPAC) with oxaliplatin for peritoneal metastasis is considered experimental and investigational because the effectiveness of this loco-regional delivery approach has not been established. Early phase trials and systematic reviews report varied dosing and limited, noncomparative safety and efficacy data; available evidence is insufficient to support routine clinical use outside of clinical studies.

    Pharmacologic and non-pharmacologic chemo-protective interventions aimed at preventing oxaliplatin-induced peripheral neuropathy are considered experimental and investigational. Systematic reviews and network meta-analyses have found the evidence for preventive strategies to be inconclusive, with many interventions showing insufficient or inconsistent data to support routine use.

    Oxaliplatin is contraindicated in individuals with a known allergy to oxaliplatin or other platinum-based compounds. The product labeling and safety information identify hypersensitivity to platinum agents as a contraindication and serious allergic reactions (including anaphylaxis) have been reported.

    Available evidence for PIPAC or HIPEC administration of oxaliplatin (PIPAC-OX/HIPEC-OX) is limited and heterogeneous. Published reports include early phase dose-escalation studies and nonrandomized series with variable doses (PIPAC doses reported starting around 45–92 mg/m2 and escalation studies up to ~300 mg/m2). The current literature does not define a clear role, optimal dosing, or comparative effectiveness; use should be confined to clinical trials or well-documented investigational programs.

    UpToDate topic reviews cited in the policy do not list oxaliplatin as a standard therapeutic option for certain contexts, for example several reviews on urothelial/bladder cancer and related management topics do not recommend oxaliplatin as a routine therapy.

    This section of the Clinical Policy Bulletin summarizes investigational/experimental listings and evidence summaries but does not state any additional explicit coverage exclusions beyond those enumerated under the ‘Experimental and Investigational’ headings.

    The Clinical Policy Bulletin is intended to assist in administering plan benefits but does not constitute a contract and provides only a partial, general description of plan or program benefits. Coverage is determined by applicable plan provisions and this bulletin may be updated.

    When preparing oxaliplatin for infusion, never prepare a final dilution with sodium chloride or other chloride-containing solutions. The product labeling specifies that final diluents must be chloride-free; using saline as the final diluent is contraindicated for preparation.

    A prior Cochrane review and subsequent updates found that, for women with metastatic breast cancer unselected for triple-negative status, platinum-based regimens provided little or no survival benefit and were associated with increased toxicity. Subgroup analyses in triple-negative metastatic breast cancer suggest a possible small survival benefit in selected patients, but overall evidence quality is limited and excess toxicity should be weighed in decision-making.

    NCCN guideline summaries and UpToDate reviews cited in the policy do not include oxaliplatin as a standard option for certain indications (for example, acute myeloid leukemia and several urothelial/bladder guideline contexts), indicating oxaliplatin is not recognized as standard-of-care in those specific guideline discussions.

    This section does not include explicit 'not medically necessary' statements framed as blanket denials for named approved indications; rather, it reports comparative effectiveness and safety findings and identifies specific tumor types and loco-regional applications (eg, PIPAC-OX) as experimental and investigational where the evidence is insufficient to support routine coverage.

    Covered Regimens and Dosing

    RegimenDose / ScheduleDurationDose modification / toxicity guidance
    FOLFOX (Eloxatin with leucovorin and 5‑FU)
    Eloxatin 85 mg/m2 IV over 120 minutes concurrently with leucovorin over 120 minutes (separate bags), followed by 5‑fluorouracil bolus and 22‑hour infusion per label (administered Day 1; Day 2 leucovorin and 5‑FU as recommended)
    Adjuvant: up to 12 cycles; Advanced/metastatic: continue until disease progression or unacceptable toxicity
    Reduce oxaliplatin to 75 mg/m2 in the adjuvant setting or to 65 mg/m2 in advanced disease for persistent grade 2 neurosensory events or after recovery from grade 3/4 GI toxicity, grade 4 neutropenia, or grade 3/4 thrombocytopenia; delay next dose until neutrophils ≥1.5 × 10^9/L and platelets ≥75 × 10^9/L; discontinue for persistent grade 3 neurosensory events
    SettingLabel-recommended doseAllowed dose reductions
    Adjuvant (stage III colon cancer)
    Oxaliplatin 85 mg/m2 IV on Day 1 every 14 days (with 5‑FU/LV per labeling); continue up to 12 cycles
    Dose reduction to 75 mg/m2 for persistent grade 2 neurosensory events or specified hematologic/GI toxicities
    Tumor type / trial contextRegimen exampleLine of therapy / evidence
    HER2‑positive advanced gastric cancer (trial settings)
    XELOX (capecitabine + oxaliplatin) plus trastuzumab; or SOX (S‑1 + oxaliplatin) plus trastuzumab
    First‑line; phase II and nonrandomized studies reporting objective responses; preliminary evidence requiring validation
    Setting / populationRegimen exampleEvidence summary
    Relapsed/refractory B‑cell non‑Hodgkin lymphoma (patients not candidates for high‑dose therapy)
    R‑GemOx (rituximab + gemcitabine 1000 mg/m2 + oxaliplatin 100 mg/m2), R‑ADOx, R‑GIFOX and similar combinations
    Phase II / pilot studies report high overall response rates (eg, R‑GemOx ORR up to 83% after 4 cycles) with acceptable tolerability in selected populations
    IndicationRegimenLine / evidence
    Biliary tract cancers (second‑line)
    FOLFOX (5‑fluorouracil/folinic acid plus oxaliplatin)
    Validated as a second‑line option after gemcitabine + cisplatin in a phase‑III trial
    RegimenComponents / dosing reportedStudy outcomes
    R‑GemOx
    Rituximab 375 mg/m2 day 1; gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 on day 2 (schedule per trial)
    Phase II data: high ORR (eg, 83% after 4 cycles in El Gnaoui et al), with acceptable safety in patients not eligible for high‑dose therapy
    IndicationRegimen examplesGuideline / trial support
    Advanced/metastatic pancreatic adenocarcinoma
    GEMOX (gemcitabine + oxaliplatin) or oxaliplatin combined with 5‑FU/irinotecan/leucovorin in multi‑agent regimens
    Supported by phase II/III trial data and NCCN guidance for patients with good performance status; GEMOX studied vs gemcitabine alone with moderate activity
    IndicationRegimen examplesNCCN category / evidence
    Neuroendocrine tumors (systemic therapy indicated)
    GEMOX (gemcitabine + oxaliplatin) or capecitabine + oxaliplatin
    NCCN lists oxaliplatin regimens as category 2A for pancreatic NETs and category 3 for carcinoid tumors; phase II data show activity
    ApplicationReported dosingEvidence / status
    Pressurized intra‑peritoneal aerosol chemotherapy (PIPAC)‑OX and HIPEC‑OX for peritoneal metastasis
    PIPAC commonly reported at ~92 mg/m2 in early reports; dose‑escalation trials have explored starting doses 45–90 mg/m2 with escalation up to 300 mg/m2
    Reported in phase I/II and systematic reviews; evidence limited and heterogeneous — considered investigational and best used in trial settings
    IndicationRegimen noteBenefit / risk summary
    Triple‑negative metastatic breast cancer (mTNBC)
    Platinum‑containing regimens (including oxaliplatin‑containing combinations) evaluated in randomized and subgroup analyses
    Meta‑analyses suggest a small survival and PFS benefit in mTNBC subgroups but with increased grade 3–4 toxicities; use should be individualized based on benefit–risk
    Example settingRegimenPhase II evidence / notes
    Non‑small cell lung cancer (NSCLC)
    Oxaliplatin + gemcitabine (GEMOX) as one explored doublet
    Phase II data show similar activity to carboplatin/gemcitabine with potentially milder hematologic toxicity; further randomized data needed
    IndicationRegimen (reported series)Reported dosing / outcomes
    Relapsed or cisplatin‑refractory testicular germ cell tumors
    GEMOX: gemcitabine 1,000 mg/m2 on days 1 and 8; oxaliplatin 130 mg/m2 on day 1 (every 3 weeks in cited series)
    Phase II series report ORRs ~32–46% with some complete responses and manageable but notable hematologic and neurotoxicities
    IndicationRegimen comparisonKey findings
    First‑line advanced gastric cancer in combination with PD‑1 inhibitors
    PD‑1 inhibitor + oxaliplatin‑based chemotherapy versus PD‑1 inhibitor + cisplatin‑based chemotherapy
    Network meta‑analysis of phase III trials (8 RCTs, 5,723 patients) found oxaliplatin‑based combinations significantly prolonged PFS and, in CPS ≥1 patients, significantly prolonged OS (HR 0.75); safety profiles were similar

    Coding and Administration

    Other CPT codes related to the CPBCPT
    96401-96450Chemotherapy administration
    96446Chemotherapy administration into the peritoneal cavity via indwelling port or catheter (pressurized intra-peritoneal aerosol chemotherapy, PIPAC)
    HCPCS codes covered when selection criteria are metHCPCSCovered
    J9263Injection, oxaliplatin, 0.5 mg
    Other HCPCS codes related to the CPBHCPCS
    Q0083-Q0085Chemotherapy administration
    Other HCPCS codes related to the CPBHCPCS
    Q0083-Q0085Chemotherapy administration
    ICD-10 codes covered when selection criteria are metICD-10Covered
    C15.3-C15.9Malignant neoplasm of esophagus
    C16.0-C16.9Malignant neoplasm of stomach (gastric carcinoma)
    C17.0-C17.9Malignant neoplasm of small intestine, including duodenum
    C18.0-C20Malignant neoplasm of colon and rectum
    C21.0-C21.8Malignant neoplasm of anus and anal canal (metastatic anal cancer)
    C22.1Intrahepatic bile duct carcinoma
    C23Malignant neoplasm of gallbladder
    C24.0Malignant neoplasm of extrahepatic bile ducts
    C24.1Malignant neoplasm of Ampulla of Vater
    C25.0-C25.9Malignant neoplasm of pancreas
    1–10 of 37
    1/4
    Administration/Drug Codes referenced but not enumeratedmixed
    Administration/drug codes referenced in background (e.g., infusion regimens) but not explicitly listed in CPT/HCPCS/NDC sections
    No explicit CPT/HCPCS/NDC codes listed in this excerptmixed
    No codes listed
    Key Administration Parameters
    Adjuvant colon cancer maximum cyclesUp to 12 cycles
    Hematologic thresholds for dosingDelay until neutrophils ≥1.5 × 10^9/L and platelets ≥75 × 10^9/L
    PIPAC oxaliplatin dose escalationStart 45-90 mg/m2; escalation up to 300 mg/m2 in 50 mg/m2 steps

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior authorization: indication and dosing verification

    Prior authorization may be required. Confirm the clinical indication (for example, adjuvant stage III colon cancer) and that dosing and regimen match FDA labeling or published guideline-supported regimens before submission.

    • Verify indication and planned regimen (e.g., Eloxatin 85 mg/m2 IV over 120 minutes with leucovorin and 5-FU per labeling for adjuvant/colorectal regimens).
    • Confirm cycle length, dose reductions, and duration (e.g., up to 12 cycles for adjuvant stage III colon cancer; continue until progression or unacceptable toxicity for advanced disease).
    Prior Authorization

    Prior authorization for systemic oxaliplatin regimens

    Prior authorization may be required for systemic oxaliplatin regimens used in combination (e.g., GEMOX for pancreatic, ovarian, or testicular salvage regimens). Document the specific indication, prior lines of therapy, and performance status as applicable.

    • Provide documentation of prior therapies and response (e.g., prior platinum exposure, prior salvage regimens).
    • State performance status when guidelines recommend use only for patients with good performance status (NCCN guidance).
    Billing Rule

    No explicit prior authorization codes listed

    No explicit prior authorization billing codes are listed in this Clinical Policy Bulletin. Use the payer’s prior authorization tool/process and reference appropriate HCPCS/CPT codes when submitting a request.

    • HCPCS: J9263 (oxaliplatin, 0.5 mg) — include when selection criteria are met.
    • Chemotherapy administration CPT range: 96401–96450 and related Q-codes (Q0083–Q0085) as applicable.
    Prior Authorization

    Prior authorization and plan provisions

    Refer to the member’s plan provisions and the Aetna Clinical Policy Bulletin for specific prior authorization requirements; this bulletin provides clinical criteria but is not a guarantee of coverage.

    • Policies and benefits (including medical necessity rules) remain subject to the member’s specific plan terms.
    • Clinical Policy Bulletins are a partial description of plan benefits and do not constitute a contract.
    Denial Risk

    Denial risk for non-adherent dosing or missing allergy documentation

    Incomplete or non-conforming documentation and dosing that contradicts FDA labeling or established regimen schedules may result in denial. Missing allergy/anaphylaxis precautions documentation is also a denial risk.

    • Document allergy history and plan for management of anaphylactic reactions (epinephrine, corticosteroids, antihistamines available).
    • Ensure dose and schedule submitted match FDA labeling or accepted guideline regimens; note any justified deviations and supporting rationale.
    Step Therapy

    Step therapy not specified

    No step therapy algorithm or mandatory sequencing rules are specified in this excerpt. Use guideline-based sequencing where applicable and document rationale when deviating from common sequences.

    • Although step therapy is not specified here, NCCN guidance informs sequencing decisions for indications such as pancreatic cancer and testicular cancer.
    • Document prior lines of therapy when requesting later-line or salvage use (e.g., GEMOX after prior platinum-based regimens).
    Note

    Sequencing note (informational)

    Informational: guideline sources note oxaliplatin can be used as an alternative or subsequent therapy in certain settings (e.g., palliative testicular cancer after first-line salvage therapy; GEMOX or oxaliplatin combinations for pancreatic adenocarcinoma in patients with good performance status).

    • NCCN supports oxaliplatin combinations for locally advanced or metastatic pancreatic adenocarcinoma and as subsequent therapy when prior fluoropyrimidine-based chemotherapy has not been given.
    • Oxaliplatin may be an alternative in palliative testicular cancer after specified salvage regimens.
    Documentation Required

    Regimen and dosing documentation

    Provide regimen, dosing, and supportive documentation with prior authorization submissions: diagnosis, tumor stage, prior therapies, rationale for oxaliplatin use, planned cycle length, dose adjustments, and monitoring plan.

    • Include tumor histology, stage, and relevant biomarker status when available (e.g., CPS for gastric cancer analyses).
    • Specify planned oxaliplatin dosing (mg/m2), infusion duration, companion agents (5-FU, leucovorin, capecitabine, gemcitabine, gemcitabine schedules), and total planned cycles.
    Documentation Required

    Trial documentation and safety reporting

    For investigational approaches or clinical trials (for example, PIPAC‑OX or other investigational intra‑peritoneal delivery), include protocol details, Clavien‑Dindo and CTCAE safety assessments, pharmacokinetic analyses, and trial outcomes when available. Experimental/Investigational uses may be denied.

    • Provide trial phase, dose-escalation schema, prior outcomes (OS, PFS, ORR), safety data (TRAEs), and PK methods when claiming medical necessity based on clinical-study evidence.
    • Document whether use is within an IRB‑approved trial and include protocol and informed consent references.
    Documentation Required

    Suggested supporting documentation

    Suggested supporting documentation: prior therapy history, objective response to prior regimens, duration of response, performance status, labs (CBC, LFTs), and any toxicity history that affects dosing. Include subgroup or biomarker results when relevant.

    • Report OS, PFS, ORR, and treatment‑related adverse events from prior lines when citing evidence for coverage.
    • Include biomarker subgroup data if used to justify regimen selection (e.g., CPS ≥1 for PD‑1 plus oxaliplatin benefit signals).

    Line of Therapy Guidance

    first-line

    First‑line (advanced colorectal cancer): Oxaliplatin in combination with infusional 5‑FU and leucovorin is an FDA‑indicated first‑line option for advanced colorectal cancer; randomized trials demonstrated improved survival versus irinotecan‑based regimens.

    second-line

    Second‑line (prior approval history): Oxaliplatin was previously approved for second‑line treatment of metastatic colorectal carcinoma for patients whose disease recurred or progressed during or within 6 months of completion of first‑line therapy with bolus 5‑FU/LV and irinotecan.

    first-line

    First‑line — adjuvant stage III colon: Adjuvant use after complete resection for stage III colon cancer is FDA‑approved; adjuvant oxaliplatin is given in combination with infusional 5‑FU/LV and supported by phase III studies demonstrating improved disease‑free survival.

    first-line

    First‑line — metastatic colorectal: Oxaliplatin in combination with 5‑FU/LV or capecitabine is indicated and supported as first‑line systemic therapy for unresectable or metastatic colon or rectal carcinoma per FDA and USP references.

    second-line

    Second‑line — biliary tract cancers: FOLFOX (5‑FU/folinic acid plus oxaliplatin) is validated as a second‑line therapy after gemcitabine+cisplatin failure in advanced biliary tract cancers based on phase‑III data.

    first-line|second-line|salvage

    First‑line | Second‑line | Salvage contexts: Oxaliplatin is used across lines depending on tumor type and setting: as salvage/regimen in relapsed/refractory B‑cell NHL (R‑GemOx) per phase II data; in first‑line clinical trials or selected first‑line settings for pancreatic combinations; and as subsequent therapy in pancreatic cancer for progressive disease in patients with good performance status per NCCN guidance.

    salvage

    Salvage — testicular germ cell tumors: Oxaliplatin‑containing regimens (eg, GEMOX, gemcitabine+oxaliplatin) have been used as salvage therapy after failure of cisplatin‑based regimens with reported response rates and some durable remissions; consider in selected patients refractory to standard therapy.

    first-line

    First‑line — advanced gastric cancer with PD‑1 inhibitor combinations: PD‑1 inhibitors plus oxaliplatin‑based chemotherapy are used as first‑line treatment for advanced gastric cancer; network meta‑analysis data suggest PFS is improved versus PD‑1 plus cisplatin‑based chemotherapy and OS is significantly improved in PD‑L1 CPS ≥1 patients.

    first-line

    First‑line — PD‑1/oxaliplatin context: Comparative analyses of PD‑1 inhibitor combinations indicate oxaliplatin‑based regimens may offer PFS and CPS‑defined OS advantages over cisplatin‑based regimens; apply biomarker (CPS) subgroup data when available.

    salvage

    Salvage — GEMOX refractory/testicular series: GEMOX has been reported as salvage therapy in relapsed or cisplatin‑refractory testicular germ cell tumors with objective responses and occasional durable remissions; hematologic toxicity and neuropathy are notable and should be documented.

    Biomarker and Test Requirements

    HER2 biomarker
    Required testing contextHER2 testing required for selection of trastuzumab-containing regimens in HER2-positive advanced gastric cancer
    Test interpretationHER2-positive status used to justify XELOX + trastuzumab first-line therapy in cited trials
    DocumentationRecord HER2 status in clinical documentation supporting use of trastuzumab with oxaliplatin
    KRAS biomarker
    Clinical contextKRAS status referenced in intra-hepatic infusion studies where cetuximab was added for KRAS wild-type tumors
    Use implicationKRAS wild-type status may influence addition of EGFR-targeted therapy in regional infusion protocols
    DocumentationReport KRAS status when intra-hepatic or regional strategies incorporate EGFR-directed agents
    MGMT promoter methylation
    MGMT methylation effectMGMT promoter methylation associated with better outcomes with alkylating agents (ALKYs) but not with GEMOX
    Regimen selection implicationGEMOX activity was not influenced by MGMT status; GEMOX may be preferred for unmethylated MGMT tumors per cited series
    Testing roleMGMT promoter methylation may guide selection between ALKY regimens and GEMOX in NETs
    PD-L1 (CPS) — CPS >=1 associated with OS benefit
    Predictive thresholdCombined Positive Score (CPS) ≥ 1 associated with significant overall survival benefit for PD-1 inhibitor plus oxaliplatin vs PD-1 plus cisplatin in advanced gastric cancer (HR 0.75)
    Outcome contextCPS ≥1 subgroup also showed significantly longer PFS with PD-1 plus oxaliplatin-based chemotherapy (HR 0.72)
    Evidence sourceFindings derived from a network meta-analysis of phase III trials including 5,723 patients
    PD-L1 (CPS) — CPS ≥1 biomarker threshold
    Biomarker thresholdPD-L1 Combined Positive Score (CPS) ≥ 1
    Use caseCPS ≥1 used to define subgroup with significant OS benefit when choosing PD-1 inhibitor plus oxaliplatin-based chemotherapy
    DocumentationRecord CPS value in clinical records supporting regimen selection for advanced gastric cancer

    Definitions and Drug Information

    Oxaliplatin (Eloxatin)
    Agent descriptionOxaliplatin (Eloxatin) — a third-generation platinum analog used intravenously in combination with 5-FU/LV for colorectal cancer
    Vial strengthsAvailable as single-dose vials in 50 mg and 100 mg strengths (5 mg/mL)
    Mechanism noteForms reactive platinum complexes that cross-link DNA (inter- and intra-strand) inhibiting DNA synthesis
    Definition — Adjuvant treatment
    DefinitionAdjuvant treatment: therapy given after complete surgical resection of the primary tumor to reduce the risk of recurrence
    Regulatory noteOxaliplatin is FDA-approved as adjuvant therapy for stage III colon cancer following complete resection
    Evidence basisApproval based on phase III studies demonstrating improved disease-free survival
    Neurologic grading
    Neurologic grading roleNeurologic (neurosensory) grading guides dose modification: persistent grade 2 → reduce dose; persistent grade 3 → discontinue
    Dose modification exampleReduce Eloxatin to 75 mg/m2 in adjuvant setting for persistent grade 2 neurosensory events
    Discontinuation criterionDiscontinue Eloxatin for persistent grade 3 neurosensory events per labeling
    PIPAC definition
    DefinitionPressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC): a laparoscopic technique delivering aerosolized chemotherapy into the peritoneal cavity
    Clinical statusPIPAC with oxaliplatin is investigational and being evaluated in phase I/II studies
    Typical reported doseInitial PIPAC reports commonly used 92 mg/m2, with dose-escalation studies starting lower (45–90 mg/m2)
    HIPEC-OX
    DefinitionHIPEC-OX: Hyperthermic Intra-Peritoneal Chemotherapy using oxaliplatin administered intra-operatively under hyperthermic conditions
    Reported dose exampleExample regimen in peritoneal mesothelioma reported HIPEC-OX at 460 mg/m2 at 43 °C for 30 minutes
    Clinical statusHIPEC-OX reported in single-center series; role requires validation in larger studies
    CPS — Combined positive score
    DefinitionCombined Positive Score (CPS): PD-L1 scoring method used to define subgroups in gastric cancer trials
    Interpretation noteCPS counts PD-L1–staining tumor and immune cells divided by total viable tumor cells ×100
    Clinical useCPS thresholds (eg, ≥1) used to identify patients more likely to derive OS benefit from PD-1 plus oxaliplatin regimens
    GEMOX — regimen definition
    Regimen componentsGEMOX: gemcitabine 1000 mg/m2 on days 1 and 8 plus oxaliplatin 130 mg/m2 on day 1 in cited series
    Indication exampleUsed as salvage therapy in refractory testicular germ cell tumors and in pancreatic/neuroendocrine contexts per trials and series
    Toxicity considerationsAssociated with hematologic toxicity (eg, grade 3 leukocytopenia and thrombocytopenia reported) and sensory neuropathy
    CPS definition repeated
    Definition repeatedCPS (Combined Positive Score) — PD-L1 biomarker used to define subgroups (eg, CPS ≥1) in network meta-analysis showing differential OS benefit
    Evidence useCPS applied in network meta-analysis of PD-1 + platinum regimens to identify OS benefit in CPS ≥1 subgroup
    RecommendationReport CPS in documentation when supporting use of PD-1 inhibitor plus oxaliplatin-based therapy
    Eloxatin (oxaliplatin) — key drug reference
    Drug referenceEloxatin (oxaliplatin) — platinum-based chemotherapeutic agent referenced across FDA labeling and clinical studies
    Common colorectal doseTypical systemic dose 85 mg/m2 IV on Day 1 of a 14-day cycle in FOLFOX regimens
    Preparation precautionNever dilute final infusion in sodium chloride or other chloride-containing solutions

    Background and Evidence Summary

    Oxaliplatin (Eloxatin) is a third-generation platinum analog administered intravenously, typically in combination with 5‑fluorouracil and leucovorin for colorectal cancer. It is supplied in single‑dose vials (commonly 50 mg or 100 mg) and forms reactive platinum complexes that cross-link DNA; a dose‑limiting toxicity is a characteristic sensory peripheral neuropathy often exacerbated by cold exposure. FDA approvals include adjuvant stage III colon cancer and treatment of advanced colorectal cancer; compendial and trial evidence support additional off‑label uses summarized elsewhere in this policy.

    Revision History & Policy Dates

    2004-03-30effective_date

    Policy originally became effective.

    2023-11-21policy_reviewLatest

    Policy last reviewed on 11/21/2023; clinical content evaluated with no material change noted.